49. The method of claim 48, wherein the contacting is *in vitro*.

50. The method of claim 48, wherein the contacting is *in vivo*.

51. The method of claim 48 or 50, wherein the contacting comprises administering the compound or the composition to a subject.

52. The method of claim 51, wherein the administering is oral, parenteral, via injection, via inhalation, transdermal, or transmucosal.

53. The method of claim 51 or 52, wherein the subject is a mammal.

54. The method of claim 53, wherein the subject is human.

55. The method of any one of claims 51 to 54, wherein the subject suffers from an autoimmune disease.

56. The method of claim 55, wherein the autoimmune disease is psoriasis, dermatitis, systemic scleroderma, sclerosis, Crohn's disease, ulcerative colitis; respiratory distress syndrome, meningitis; encephalitis; uveitis; colitis; glomerulonephritis; eczema, asthma, chronic inflammation; atherosclerosis; leukocyte adhesion deficiency; rheumatoid arthritis; systemic lupus erythematosus (SLE); diabetes mellitus (e.g., Type I diabetes mellitus or insulin dependent diabetes mellitus); multiple sclerosis; Reynaud's syndrome; autoimmune thyroiditis; allergic encephalomyelitis; Sjorgen's syndrome; juvenile onset diabetes; tuberculosis, sarcoidosis, polymyositis, granulomatosis and vasculitis; pernicious anemia (Addison's disease); diseases involving leukocyte diapedesis; central nervous system (CNS) inflammatory disorder; multiple organ injury syndrome; hemolytic anemia; myasthenia gravis; antigen-antibody complex mediated diseases; anti-glomerular basement membrane disease; antiphospholipid syndrome; allergic neuritis; Graves' disease; Lambert-Eaton myasthenic syndrome; pemphigoid bullous; pemphigus; autoimmune polyendocrinopathies; Reiter's disease; stiff-man syndrome; Beheet disease; giant cell arteritis; immune complex nephritis; IgA nephropathy; IgM polyneuropathies; immune thrombocytopenic purpura (ITP) or autoimmune thrombocytopenia.

57. A method for the treatment of an immune-related disease, comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 46 or the composition of claim 47 to a subject in need thereof.

58. The method of claim 57, wherein the immune-related disease is rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, or Crohn's disease

59. A method for the treatment of cancer, comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 46 or the composition of claim 47 to a subject in need thereof.

60. The method of claim 59, wherein the cancer is prostate cancer.

61. A method for the treatment of inflammation, comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 46 or the composition of claim 47 to a subject in need thereof.

62. A method for treating infection, comprising administering a therapeutically effective amount of a compound of the compound of any one of claims 1 to 46 or the composition of claim 47 to a subject in need thereof.

63. A method for treating proliferative disease, comprising administering a therapeutically effective amount of the compound of any one of claims 1 to 46 or the composition of claim 47 to a subject in need thereof.

64. A method for treating neurodegenerative disease, compromising administering a therapeutically effective amount of the compound of any one of claims 1 to 46 or the composition of claim 47 to a subject in need thereof.

65. The method of claim 64, wherein the neurodegenerative disease is multiple sclerosis.

49. The method of claim 48, wherein the contacting is *in vitro*.

50. The method of claim 48, wherein the contacting will involve administration of the compound or the composition to a subject.

51. The method of claim 50, wherein the administration is to be oral, parenteral, via injection, via inhalation, transdermal, or transmucosal.

52. The method of claim 50 or 51, wherein the subject is a mammal.

53. The method of claim 52, wherein the subject is human.

54. The method of any one of claims 50 to 53, wherein the subject suffers from an autoimmune disease.

55. The method of claim 54, wherein the autoimmune disease is psoriasis, dermatitis, systemic scleroderma, sclerosis, Crohn's disease, ulcerative colitis; respiratory distress syndrome, meningitis; encephalitis; uveitis; colitis; glomerulonephritis; eczema, asthma, chronic inflammation; atherosclerosis; leukocyte adhesion deficiency; rheumatoid arthritis; systemic lupus erythematosus (SLE); diabetes mellitus (e.g., Type I diabetes mellitus or insulin dependent diabetes mellitus); multiple sclerosis; Reynaud's syndrome; autoimmune thyroiditis; allergic encephalomyelitis; Sjorgen's syndrome; juvenile onset diabetes; tuberculosis, sarcoidosis, polymyositis, granulomatosis and vasculitis; pernicious anemia (Addison's disease); diseases involving leukocyte diapedesis; central nervous system (CNS) inflammatory disorder; multiple organ injury syndrome; hemolytic anemia; myasthenia gravis; antigen-antibody complex mediated diseases; anti-glomerular basement membrane disease; antiphospholipid syndrome; allergic neuritis; Graves' disease; Lambert-Eaton myasthenic syndrome; pemphigoid bullous; pemphigus; autoimmune polyendocrinopathies; Reiter's disease; stiff-man syndrome; Beheet disease; giant cell arteritis; immune complex nephritis; IgA nephropathy; IgM polyneuropathies; immune thrombocytopenic purpura (ITP) or autoimmune thrombocytopenia.

56. A therapeutically effective amount of the compound of any one of claims 1 to 46 or the composition of claim 47 for use in the treatment of an immune-related disease, wherein the compound or the composition is to be administered to a subject in need thereof.

57. The use of a therapeutically effective amount of the compound or the composition of any one of claims 1 to 46 or the composition of claim 47 in the manufacture of a medicament for the treatment of an immune-related disease.

58. The compounds or the composition of claim 56, wherein the immune-related disease is rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, or Crohn's disease.

59. The use of claim 57, wherein the immune-related disease is rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, or Crohn's disease.

60. A therapeutically effective amount of the compound of any one of claims 1 to 46 or the composition of claim 47 for use in the treatment of cancer, wherein the compound or the composition is to be administered to a subject in need thereof.

61. The use of a therapeutically effective amount of the compound or the composition of any one of claims 1 to 46 or the composition of claim 47 in the manufacture of a medicament for the treatment of cancer.

62. The compounds or the composition of claim 60, wherein the cancer is prostate cancer.

63. The use of claim 61, wherein the cancer is prostate cancer.

64. A therapeutically effective amount of the compound of any one of claims 1 to 46 or the composition of claim 47 for use in the treatment of inflammation, wherein the compound or the composition is to be administered to a subject in need thereof.

65. The use of a therapeutically effective amount of the compound or the composition of any one of claims 1 to 46 or the composition of claim 47 in the manufacture of a medicament for the treatment of inflammation.

66. A therapeutically effective amount of a compound of the compound of any one of claims 1 to 46 or the composition of claim 47 for use in the treatment of infection, wherein the compound or the composition is to be administered to a subject in need thereof.

67. The use of a therapeutically effective amount of the compound or the composition of any one of claims 1 to 46 or the composition of claim 47 in the manufacture of a medicament for the treatment of infection.

68. A therapeutically effective amount of the compound of any one of claims 1 to 46 or the composition of claim 47 for use in the treatment of proliferative disease, wherein the compound or the composition is to be administered to a subject in need thereof.

69. The use of a therapeutically effective amount of the compound or the composition of any one of claims 1 to 46 or the composition of claim 47 in the manufacture of a medicament for the treatment of proliferative disease.

70. A therapeutically effective amount of the compound of any one of claims 1 to 46 or the composition of claim 47 for use in the treatment of neurodegenerative disease, wherein the compound or the composition is to be administered to a subject in need thereof.

71. The use of a therapeutically effective amount of the compound or the composition of any one of claims 1 to 46 or the composition of claim 47 in the manufacture of a medicament for the treatment of neurodegenerative disease.

72. The compounds or the composition of claim 70, wherein the neurodegenerative disease is multiple sclerosis.

73. The use of claim 71, wherein the neurodegenerative disease is multiple sclerosis.